Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives

被引:65
作者
Herradon, G. [1 ]
Perez-Garcia, C. [1 ]
机构
[1] Univ CEU San Pablo, Fac Pharm, Dept Pharmaceut & Hlth Sci, Pharmacol Lab, Madrid 28668, Spain
关键词
Parkinson's disease; Alzheimer's disease; amphetamine; cocaine; methamphetamine; relapse; drug abuse; cannabinoid; neurotoxicity; ALK; PROTEIN-TYROSINE-PHOSPHATASE; BINDING GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; NIGROSTRIATAL DOPAMINE SYSTEM; DEVELOPMENTAL GENE FAMILY; RENIN-ANGIOTENSIN SYSTEM; INDUCED PLACE PREFERENCE; BLOOD-BRAIN-BARRIER; RECEPTOR-TYPE-Z; PARKINSONS-DISEASE;
D O I
10.1111/bph.12312
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Midkine (MK) and pleiotrophin (PTN) are two neurotrophic factors that are highly up-regulated in different brain regions after the administration of various drugs of abuse and in degenerative areas of the brain. A deficiency in both MK and PTN has been suggested to be an important genetic factor, which confers vulnerability to the development of the neurodegenerative disorders associated with drugs of abuse in humans. In this review, evidence demonstrating that MK and PTN limit the rewarding effects of drugs of abuse and, potentially, prevent drug relapse is compiled. There is also convincing evidence that MK and PTN have neuroprotective effects against the neurotoxicity and development of neurodegenerative disorders induced by drugs of abuse. Exogenous administration of MK and/or PTN into the CNS by means of non-invasive methods is proposed as a novel therapeutic strategy for addictive and neurodegenerative diseases. Identification of new molecular targets downstream of the MK and PTN signalling pathways or pharmacological modulation of those already known may also provide a more traditional, but probably effective, therapeutic strategy for treating addictive and neurodegenerative disorders. Linked ArticlesThis article is part of a themed section on Midkine. To view the other articles in this section visit
引用
收藏
页码:837 / 848
页数:12
相关论文
共 134 条
[1]   Creatine and Its Potential Therapeutic Value for Targeting Cellular Energy Impairment in Neurodegenerative Diseases [J].
Adhihetty, Peter J. ;
Beal, M. Flint .
NEUROMOLECULAR MEDICINE, 2008, 10 (04) :275-290
[2]   THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: OVERVIEW [J].
Alexander, Stephen P. H. ;
Benson, Helen E. ;
Faccenda, Elena ;
Pawson, Adam J. ;
Sharman, Joanna L. ;
McGrath, John C. ;
Catterall, William A. ;
Spedding, Michael ;
Peters, John A. ;
Harmar, Anthony J. .
BRITISH JOURNAL OF PHARMACOLOGY, 2013, 170 (08) :1449-1458
[3]   GDNF, NGF and BDNF as therapeutic options for neurodegeneration [J].
Allen, Shelley J. ;
Watson, Judy J. ;
Shoemark, Deborah K. ;
Barua, Neil U. ;
Patel, Nikunj K. .
PHARMACOLOGY & THERAPEUTICS, 2013, 138 (02) :155-175
[4]   Functional significance of aldehyde dehydrogenase ALDH1A1 to the nigrostriatal dopamine system [J].
Anderson, David W. ;
Schray, Rebecca C. ;
Duester, Gregg ;
Schneider, Jay S. .
BRAIN RESEARCH, 2011, 1408 :81-87
[5]   The role of dopamine receptors in the neurotoxicity of methamphetamine [J].
Ares-Santos, S. ;
Granado, N. ;
Moratalla, R. .
JOURNAL OF INTERNAL MEDICINE, 2013, 273 (05) :437-453
[6]   Principles of strategic drug delivery to the brain (SDDB): Development of anorectic and orexigenic analogs of leptin [J].
Banks, W. A. ;
Gertler, A. ;
Solomon, G. ;
Niv-Spector, L. ;
Shpilman, M. ;
Yi, X. ;
Batrakova, E. ;
Vinogradov, S. ;
Kabanov, A. V. .
PHYSIOLOGY & BEHAVIOR, 2011, 105 (01) :145-149
[7]   Activation of signaling pathways following localized delivery of systemically administered neurotrophic factors across the blood-brain barrier using focused ultrasound and microbubbles [J].
Baseri, Babak ;
Choi, James J. ;
Deffieux, Thomas ;
Samiotaki, Gesthimani ;
Tung, Yao-Sheng ;
Olumolade, Oluyemi ;
Small, Scott A. ;
Morrison, Barclay, III ;
Konofagou, Elisa E. .
PHYSICS IN MEDICINE AND BIOLOGY, 2012, 57 (07) :N65-N81
[8]   Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs [J].
Callaghan, Russell C. ;
Cunningham, James K. ;
Sykes, Jenna ;
Kish, Stephen J. .
DRUG AND ALCOHOL DEPENDENCE, 2012, 120 (1-3) :35-40
[9]   Intranasal "painless" Human Nerve Growth Factors Slows Amyloid Neurodegeneration and Prevents Memory Deficits in App X PS1 Mice [J].
Capsoni, Simona ;
Marinelli, Sara ;
Ceci, Marcello ;
Vignone, Domenico ;
Amato, Gianluca ;
Malerba, Francesca ;
Paoletti, Francesca ;
Meli, Giovanni ;
Viegi, Alessandro ;
Pavone, Flaminia ;
Cattaneo, Antonino .
PLOS ONE, 2012, 7 (05)
[10]  
Chapman CD, 2012, PHARM RES